Everyone seems to be in London this week, including Heptares – a biotech which is a rising STAR in Neurological disease partnerships. I caught up with its co-founder and CEO Malcolm Weir on their latest accomplishments…

gpcr_heptares_biotech_london_biotrinityHeadquartered in Welwyn Garden City (just a 25 minute train ride north of London), Heptares is a growing name in the biotech field thanks to their CGRP small-molecule program. It currently has partnerships with many huge players in the CNS field.

As discussed before on Heptares’ partnership with US-Israeli Giant Teva, is what makes Heptares such an attractive partner is their GPCR platform. This small-molecule platform has an extensive number of applications and targets available.

Many have seen its potential too, as evident with a billion-euro discovery deal with Pfizer, a €3Bn deal with Allergan for Alzheimer’s research, and other partnerships with Takeda, MorphoSys, MedImmune and Cubist Pharma (US).

Here I asked Malcolm to explain a bit more on how their platform works, and how being a wholly-owned Subsidiary of Japan’s Sosei Group worked regarding business…

Here’s the interview…

Feature Image Credit: Philip Hemme interview Malcolm Weir at BioTrinity 2016
Previous post

French Pleodrug for Rare Neurological Disease opens up phase III trial in US

Next post

'Disappointing results' for Novartis & MorphoSys phase III in Muscle Disease